Elkind Arthur H, MacGregor E Anne
Elkind Headache Center, 12 North Seventh Avenue, Mount Vernon, NY 10550, USA.
Expert Rev Neurother. 2008 May;8(5):723-36. doi: 10.1586/14737175.8.5.723.
Frovatriptan is a 5-HT(1B/1D) receptor agonist that belongs to the triptan therapeutic class. Relative to other triptans, frovatriptan has a long half-life (26 h) and a low incidence of migraine recurrence (17%). Frovatriptan is indicated for the acute treatment of migraine with or without aura, and has a relatively good safety and tolerability profile. Recent studies have also shown that a 6-day regimen of frovatriptan scheduled during the perimenstrual period significantly reduced the incidence and severity of menstrual migraine (MM; attacks that regularly start day -2 to +3 relative to menses). Prevention may be important because MM attacks have been characterized as being of longer duration, more severe and more refractory to treatment than non-MM attacks.
夫罗曲普坦是一种5-HT(1B/1D)受体激动剂，属于曲坦类治疗药物。与其他曲坦类药物相比，夫罗曲普坦半衰期长（26小时），偏头痛复发率低（17%）。夫罗曲普坦适用于有或无先兆偏头痛的急性治疗，安全性和耐受性相对良好。最近的研究还表明，在围经期安排6天的夫罗曲普坦治疗方案可显著降低月经性偏头痛（MM；相对于月经周期，通常在第-2天至+3天开始发作）的发病率和严重程度。预防可能很重要，因为与非月经性偏头痛发作相比，月经性偏头痛发作的特点是持续时间更长、更严重且对治疗更具难治性。
